7 results about "Gastroparesis" patented technology

Embodiments include a method of diagnosing gastroparesis or suspected gastroparesis, the method comprising: obtaining data representing a time series of readings from gas sensing apparatus housed within a ingestible capsule device orally ingested by a subjected; processing the readings to detect one or more gastroparesis indicator spikes in the CO2 concentration with respect to time; based on the detected one or more gastroparesis indicator spikes in the CO2 concentration with respect to time, diagnosing gastroparesis or suspected gastroparesis.

A method for treating conditions of the gastrointestinal tract of a subject using a vibrating ingestible capsule ingested by the subject and activated in a targeted zone of the gastrointestinal tract of the subject. The conditions may include a sensation of gastric bloating, a sensation of straining during defecating, diarrhea and / or gastroparesis. The method is further suitable for reducing Bristol stool scores of fecal matter of the subject and for increasing a Bristol stool score of fecal matter of the subject.

The invention provides a traditional Chinese medicine external application composition for treating gastroparesis after brain injury and a preparation method thereof. The traditional Chinese medicine external application composition is prepared from the following components: rhizoma acori graminei, paederia scandens, radix polygoni multiflori preparata, aloe, gastrodia elata, semen aesculi, phyllanthus emblica, stephania tetrandra, turmeric, radix fici simplicissimae, fructus piperis longi, swertia pseudochinensis, rhizoma nardostachyos, lily, ginkgo leaves and cynanchum paniculatum. Dual mechanisms of neuroprotection and gastrointestinal motility regulation are creatively fused, central nervous injury can be improved through components such as rhizoma acori graminei and radix polygoni multiflori preparata, gastrointestinal hormone secretion and slow-wave pace-making functions can be synchronously regulated through components such as paederia scandens and turmeric, and compared with a conventional single-target treatment means, the traditional Chinese medicine composition is more suitable for a complex pathological mechanism of gastric paralysis after brain injury. Meanwhile, the preparation process is simple, the cost is low, external application avoids aggravation of gastrointestinal burdens, common western medicine side effects such as arrhythmia are avoided, clinical operation is convenient, patient tolerance is good, the gastric emptying recovery time is remarkably shortened, and the risk of complications such as aspiration pneumonia is reduced.

The invention provides a pharmaceutical composition for preventing and treating metabolic syndrome, resisting islet injury and promoting gastrointestinal function. The pharmaceutical composition is an oral preparation prepared from traditional Chinese medicinal raw materials or raw material extracts according to the following weight ratio. The raw material composition comprises the following medicinal materials and decoction pieces in parts by weight: 6-60 parts of fenugreek and 6-60 parts of inula flower. The traditional Chinese medicine composition comprises the following raw material extracts in parts by weight: 1-20 parts of fenugreek extract and 1-25 parts of inula flower extract. The pharmaceutical composition disclosed by the invention can effectively reduce blood sugar, triglyceride and cholesterol, improve insulin tolerance and hyperinsulinemia, improve glucose tolerance, relieve pancreas islet injury and promote gastrointestinal motility. The composition is good in safety, can be clinically used for preventing and treating the metabolic syndrome and protecting pancreas islet in the early stage, and can also be used for treating gastric paralysis and constipation.

The disclosure provides pharmaceutical formulations comprising d4-domperidone of the formula (I):or a pharmaceutically acceptable salt thereof. The formulations also contain (i) a glyceryl stearate, and a medium chain triglyceride; or (ii) a stearoyl polyoxyl glyceride, a nonionic poly(ethylene oxide) polymer, and a medium chain triglyceride; or (iii) a nonionic poly(ethylene oxide) polymer, and a polyethylene glycol. The disclosure also provides methods for treating a disorder that is gastroparesis, nausea apart from gastroparesis, vomiting apart from gastroparesis, nausea associated with gastroparesis, vomiting associated with gastroparesis, gastroesophageal reflux disease, insufficient lactation, or a combination thereof in a patient, comprising administering to the patient a formulation described herein. In some aspects, the disorder is gastroparesis. In other aspects, the disorder is gastroesophageal reflux disease. In further aspects, the disorder is insufficient lactation.

Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3′R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3′-yl ester di-hydrochloride salt. Provided are also pharmaceutical compositions and dosage forms comprising the trihydrate form, and methods and uses for treating a gastrointestinal disorder in a subject with the trihydrate form. In some embodiments, the gastrointestinal disorder is gastroesophageal reflux disease (GERD), dyspepsia (such as functional dyspepsia or functional motility disorder), gastroparesis, paralytic ileus, post-operative ileus, emesis, nausea, heartburn, intestinal pseudo-obstruction, irritable bowel syndrome (IBS), constipation, enteral feeding intolerance (EFI), or esophagitis. In some embodiments, the gastrointestinal disorder is post-operative ileus, chronic grass sickness, constipation, megacolon, gastritis, gastrointestinal stasis, or abomasal emptying defect.

Disclosed herein are compositions and methods for use in treating gastroparesis.